Poor Response to Alprostadil ICI Test is Associated with Arteriogenic Erectile Dysfunction and Higher Risk of Major Adverse Cardiovascular Events

Journal of Sexual Medicine

Volumn 8, Issue 12, 2011, Pages 3433-3445

  Rastrelli, Giulia ^a   Corona, Giovanni ^a,b   Monami, Matteo ^a   Melani, Cecilia ^c   Balzi, Daniela ^c   Sforza, Alessandra ^b   Forti, Gianni ^a   Mannucci, Edoardo ^a   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c Epidemiology Unit   (Italy)

Author keywords

Cardiovascular diseases; Erectile dysfunction; Intracavernous alprostadil injection test; Penile doppler ultrasound

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; TESTOSTERONE;

ADULT; ADVERSE OUTCOME; AGING; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CIGARETTE SMOKING; COLOR ULTRASOUND FLOWMETRY; CORPUS CAVERNOSUM; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; ERECTILE DYSFUNCTION; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HAZARD RATIO; HETEROSEXUALITY; HUMAN; HYPERTENSION; HYPOGONADISM; INJECTION; INTERNATIONAL CLASSIFICATION OF DISEASES; INTRACAVERNOUS ALPROSTADIL INJECTION TEST; LONGITUDINAL STUDY; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; METABOLIC DISORDER; MORBIDITY; OBESITY; OUTCOME ASSESSMENT; PENILE BLOOD FLOW; PENILE COLOR DOPPLER ULTRASOUND; PENIS; PENIS ERECTION; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; STRUCTURED INTERVIEW; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

EID: 82955203373     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02474.x     Document Type: Article

References (41)

1. Petrone L, Mannucci E, Corona G, Bartolini M, Forti G, Giommi R, Maggi M. Structured interview on erectile dysfunction (SIEDY©): A new, multi-dimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res 2003;15:210-20.
2. Corona G, Forti G, Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male 2008;11:193-9.
3. Corona G, Fagioli G, Mannucci E, Romeo A, Rossi M, Lotti F, Sforza A, Morittu S, Chiarini V, Casella G, Di Pasquale G, Bandini E, Forti G, Maggi M. Penile Doppler ultrasound in patients with ED: Role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med 2008;5:2623-34.
4. Corona G, Monami M, Boddi V, Cameron-Smith M, Lotti F, de Vita G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Male sexuality and cardiovascular risk. A cohort study in patients with erectile dysfunction. J Sex Med 2010;7:1918-27.
5. Seftel AD. Diagnosis of erectile dysfunction. In: Porst H, Buvat J, eds. Standard practice in sexual medicine. Malden, MA: Blackwell Publishing; 2006:p67.
6. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y, EAU. EAU Guidelines on erectile dysfunction: An update. Eur Urol 2006;49:806-15.
7. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Milbank AJ, Nehra A, Sharlip ID, Erectile Dysfunction Guideline Update Panel. Chapter 1: The management of erectile dysfunction: An AUA update. J Urol 2005;174:230-9.
8. McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med 2007;357:2472-81.
9. Hackett G, Kell P, Ralph D, Dean J, Price D, Speakman M, Wylie K, British Society for Sexual Medicine. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008;5:1841-65.
10. Virag R, Frydman D, Legman M, Virag H. Intracavernous injection of papaverine as a diagnostic and therapeutic method in erectile failure. Angiology 1984;23:35-79.
11. Lue TF. Impotence: A patient's goal directed approach to treatment. World J Urol 1990;8:67-75.
12. Aversa A, Isidori AM, Caprio M, Cerilli M, Frajese V, Fabbri A. Penile pharmacotesting in diagnosing male erectile dysfunction: Evidence for lack of accuracy and specificity. Int J Androl 2002;25:6-10.
13. Lehmann K, Eichlisberger R, Gasser TC. Lack of diagnostic tools to prove erectile dysfunction: Consequences for reimbursement. J Urol 2000;163:91-4.
14. Gontero P, Sriprasad S, Wilkins CJ, Donaldson N, Muir GH, Sidhu PS. Phentolamine re-dosing during penile dynamic colour Doppler ultrasound: A practical method to abolish a false diagnosis of venous leakage in patients with erectile dysfunction. Br J Radiol 2004;77:922-6.
15. Hatzichristou DG, Saenz de Tejada I, Kupferman S, Namburi S, Pescatori ES, Udelson D, Goldstein I. In vivo assessment of trabecular smooth muscle tone, its application in pharmaco-cavernosometry and analysis of intracavernous pressure determinants. J Urol 1995;153:1126-35.
16. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, Vardi Y, Wespes E, European Association of Urology. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804-14.
17. Hatzichristou D, Rosen R, Derogatis L, Low WY, Meuleman E, Sadvsky R, Symonds T. Clinical evaluation and symptom scales in men and women with sexual dysfunction. In: Montorsi F, Basson R, Adaikan G, Becher E, Clayton A, Giuliano F, Khoury S, Sharlip I, eds. Sexual Medicine: Sexual Dysfunctions in Men and Women. The 3rd International Consultation on Sexual Medicine. Paris, France: Health Publication Ltd; 2010:229-80.
18. Crown S, Crisp AH. A short clinical diagnostic self-rating scale for psychoneurotic patients. The Middlesex Hospital Questionnaire (M.H.Q.). Br J Psychiatry 1966;112:917-23.
19. McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS, Fink JC, Langenberg P, Roghmann MC, Harris AD. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibioticresistant organisms. Am J Epidemiol 2005;161:483-93.
20. Palmieri L, Panico S, Vanuzzo D, Ferrario M, Pilotto L, Sega R, Cesana G, Giampaoli S, Gruppo di Ricerca del Progetto CUORE. Evaluation of the global cardiovascular absolute risk: The Progetto CUORE individual score. Ann Ist Super Sanita 2004;40:393-9.
21. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002;105:310-5.
22. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
23. Lehmann K, John H, Kacl G, Hauri D, Gasser TC. Variable response to intracavernous prostaglandin E1 testing for erectile dysfunction. Urology 1999;54:539-43.
24. Mancini M, Bartolini M, Maggi M, Innocenti P, Forti G. The presence of arterial anatomical variations can affect the results of duplex sonographic evaluation of penile vessels in impotent patients. J Urol 1996;155:1919-23.
25. Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, de Vita G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med 2010;7:1557-64.
26. Aversa A, Rocchietti-March M, Caprio M, Giannini D, Isidori A, Fabbri A. Anxiety-induced failure in erectile response to intracorporeal prostaglandin-E1 in non-organic male impotence: A new diagnostic approach. Int J Androl 1996;19:307-13.
27. Van Tongeren RB, Bastiaansen AJ, Van Wissen RC, Le Cessie S, Hamming JF, Van Bockel JH. A comparison of the Doppler-derived maximal systolic acceleration versus the ankle-brachial pressure index or detecting and quantifying peripheral arterial occlusive disease in diabetic patients. J Cardiovasc Surg (Torino) 2010;51:391-8.
28. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011;25:337-53.
29. Corona G, Rastrelli G, Monami M, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Body mass index regulates hypogonadism-associated CV risk: Results from a cohort of subjects with erectile dysfunction. J Sex Med 2011;8:2098-105.
30. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632-8.
31. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010;7:46-56.
32. Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol 2004;171:2358-62.
33. Filippi S, Vignozzi L, Morelli A, Chavalmane AK, Sarchielli E, Fibbi B, Saad F, Sandner P, Ruggiano P, Vannelli GB, Mannucci E, Maggi M. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med 2009;6:3274-88.
34. Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 1994;79:997-1000.
35. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993;76:1140-6.
36. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, Rosenfeld RS. Plasma free and non-sex-hormonebinding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990;71:929-31.
37. Corona G, Mannucci E, Fisher AD, Lotti F, Petrone L, Balercia G, Bandini E, Forti G, Maggi M. Low levels of androgens in men with erectile dysfunction and obesity. J Sex Med 2008;5:2454-63.
38. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC, EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European male ageing study. J Clin Endocrinol Metab 2010;95:1810-8.
39. Jannini EA, Screponi E, Carosa E, Pepe M, Lo Giudice F, Trimarchi F, Benvenga S. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 1999;22:385-92.
40. Carosa E, Benvenga S, Trimarchi F, Lenzi A, Pepe M, Simonelli C, Jannini EA. Sexual inactivity results in reversible reduction of LH bioavailability. Int J Impot Res 2002;14:93-9.
41. Carosa E, Martini P, Brandetti F, Di Stasi SM, Lombardo F, Lenzi A, Jannini EA. Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. Clin Endocrinol (Oxf) 2004;61:382-6.